The abstract is read at the publisher; the summary is JClub's.
PD-1 blockade during primary hepatitis E virus infection in humans enhances clonal expansion and terminal differentiation of de novo HEV-specific CD8+ T-cells, yielding long-lived effector-like cells rather than classical memory.
- Why it matters: Immune checkpoint inhibitors can alter T-cell targeting during acute hepatitis, but how PD-1 blockade reshapes antiviral CD8+ T-cell fate and memory development during primary HEV infection was unclear.
- What they did: The study profiled HEV-specific CD8 and CD4+ T-cells in ICI-treated versus untreated patients using reverse phenotyping with single-cell transcriptomics and TCR sequencing, plus MHC class I tetramers and multiparameter flow cytometry.
- The result: HEV-specific T-cells persisted for over 2 years under ICI, but functional recall responsiveness declined, implying PD-1 blockade favors terminal effector-like states over conventional memory formation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.